Retatrutide appears to have a similar safety profile to other GLP-1 medications: No increased risk of pancreatitis in trials so far No hepatotoxicity signals (liver damage) No cases of ketoacidosis Serious adverse events were rare (2.5% of participants) The trials are ongoing, so we'll learn more about long-term safety
the most common issues are mild injection-site redness or swelling, transient fatigue, and occasional flu-like symptoms
Knowing the difference between normal adjustment and concerning signs helps you respond appropriately
Iwai S, Kaji K, Nishimura N, Kubo T, Tomooka F, Shibamoto A, et al
Given the complexity of this triple agonist peptide structure, our analytical protocols include additional quality checks for correct folding and modification integrity